\-\ Texto\\:\\ \ \(0\)\
\-\ bcva\\:\\ 20\\/20\\ \\-2\\ ou\\ \\ \\ \\(low\\ myope\\ ou\\)\ \(0\)\
\-\ color\\ vision\\ \\(pip\\)\\:\\ 10\\/14\\ od\\ \\ 11\\/14\\ os\ \(0\)\
\-\ red\\ desaturation\\:\\ 90\\%\\ od\ \(0\)\
\-\ white\\ light\\ brightness\\:\\ 75\\%\\ od\ \(0\)\
\-\ pupils\\:\\ 4\\-\\>3mm\\ ou\\,\\ \\ \\ \\ 2\\+\\ apd\\ od\ \(0\)\
\-\ motility\\:\\ fd\\ \\&\\ v\\ ou\ \(0\)\
\-\ visual\\ fields\\:\\ gross\\ defect\\ to\\ confrontation\\ 7\\-9\\ clock\\ hours\\ od\\;\\ full\\ os\ \(0\)\
\-\ iop\\:\\ 16\\ ou\ \(0\)\
\-\ sle\\:\\ normal\\ anterior\\ segment\\ ou\ \(0\)\
\-\ dfe\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ lens\\/vitreous\\:\\ clear\\ ou\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ macula\\:\\ \\+flr\\,\\ flat\\ and\\ unremarkable\\ ou\ \(0\)\
\-\ \\ \\ \\ \\ \\ a\\/v\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ normal\\ caliber\\ w\\/o\\ nicking\\,\\ tortuosity\\,\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ attenuation\\,\\ or\\ sheathing\\ ou\ \(0\)\
\-\ \\ \\ \\ \\ \\ periphery\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ flat\\ and\\ unremarkable\\ ou\ \(0\)\
\-\ \\ \\ \\ \\ \\ disc\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ 0\\.1\\ c\\/d\\ ou\\ w\\/o\\ pallor\\/heme\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ slightly\\ increased\\ fullness\\/elevation\\ od\\,\\ but\\ \\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ sharp\\ disc\\ margins\\/clearly\\-defined\\ vessels\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ single\\ flat\\,\\ hypopigmented\\ lesion\\ just\\ inferior\\ \\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ to\\ disc\\ margin\\ od\\ \\(1\\/5\\ dd\\)\ \(0\)\
\-\ trans\\-sphenoidal\\ surgical\\ debulking\\ \\(uncomplicated\\)\ \(0\)\
\-\ serology\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ bartonella\ \(0\)\
\-\ \\ \\ \\ \\ \\ lyme\ \(0\)\
\-\ \\ \\ \\ \\ \\ rpr\\/fta\ \(0\)\
\-\ mri\\ orbits\ \(0\)\
\-\ presumably\\ new\\-onset\\,\\ painless\\,\\ diffuse\\ r\\ monocular\\ field\\ loss\\ \\ w\\/\\ \\+apd\\ and\\ subtle\\ abnormalities\\ of\\ r\\ optic\\ disc\ \(0\)\
\-\ large\\ intrasellar\\ and\\ suprasellar\\ mass\\ lesion\ \(0\)\
\-\ pituitary\\ macroadenoma\\ \\-\\ null\\ cell\\ \\(non\\-secreting\\)\ \(0\)\
\-\ optic\\ nerve\\ disease\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ neuropathy\\:\\ compressive\\/infiltrative\\,\\ \\ \\ \\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ inflammatory\\,\\ ischemic\\,\\ toxic\ \(1\)\
\-\ \\ \\ \\ \\ \\ optic\\ nerve\\ drusen\ \(1\)\
\-\ retrobulbar\\ optic\\ neuritis\\ \ \(0\)\
\-\ neuroretinitis\\ \\(bartonella\\,\\ syphilis\\,\\ lyme\\)\ \(0\)\
\-\ intracranial\\ process\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\-\\ mass\\ \\(pit\\ adenoma\\,\\ meningioma\\,\\ glioma\\,\\ \\ \\ \\ \\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ craniopharygioma\\)\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\-\\ aneurysm\\ \\(most\\ likely\\ ica\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ inflammation\\ \\(sarcoid\\,\\ ms\\)\ \(0\)\
\-\ retinal\\ dystrophy\\/degeneration\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\-\\ fundus\\ flavimaculatus\ \(1\)\
\-\ 21\\ y\\.o\\.\\ woman\\ reservist\\,\\ activated\\ \\&\\ deployed\\ into\\ iraq\\ in\\ march\\.\ \(0\)\
\-\ air\\ evacuated\\ to\\ germany\\ and\\ then\\ subsequently\\ to\\ wramc\\ in\\ mid\\ july\\ for\\ dyspnea\\.\ \(0\)\
\-\ pulmonology\\ evaluation\\ made\\ a\\ diagnosis\\ of\\ asthma\\,\\ and\\ she\\ was\\ started\\ on\\ po\\ steroid\\ burst\\ w\\/\\ taper\\,\\ albuterol\\,\\ advair\\ and\\ singulaire\\.\\ \\ \ \(0\)\
\-\ r\\-sided\\ visual\\ loss\\ \\(od\\)\\ started\\ shortly\\ after\\ initiating\\ these\\ asthma\\ meds\\ and\\ remained\\ stable\\ over\\ next\\ 1\\-2\\ weeks\\.\\ \\ she\\ then\\ reported\\ \\â\\€\\œi\\ can\\â\\€\\™t\\ see\\ person\\ standing\\ to\\ my\\ right\\â\\€\\\\.\\ \ \(0\)\
\-\ she\\ denied\\ any\\ sudden\\ onset\\ \\-\\ but\\ is\\ unable\\ to\\ pinpoint\\ the\\ moment\\ when\\ her\\ symptoms\\ began\\ nor\\ recall\\ what\\ she\\ was\\ doing\\;\\ no\\ \\â\\€\\œfalling\\ curtain\\â\\€\\\\.\ \(0\)\
\-\ no\\ central\\ vision\\ loss\\ ou\ \(0\)\
\-\ no\\ vision\\ changes\\ os\ \(0\)\
\-\ no\\ floaters\\,\\ photopsia\\ or\\ amaurosis\\ \ \(1\)\
\-\ no\\ headache\\,\\ eye\\ pain\\ or\\ photophobia\\ \ \(1\)\
\-\ no\\ gross\\ neurologic\\ symptoms\\ \\(diplopia\\,\\ dysarthria\\,\\ weakness\\,\\ parasthesias\\,\\ confusion\\)\ \(1\)\
\-\ pmh\\/psh\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ recent\\ asthma\\ dx\ \(1\)\
\-\ fh\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ non\\-contributory\ \(1\)\
\-\ social\\ hx\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ no\\ tobacco\\/rare\\ etoh\ \(0\)\
\-\ \\ \\ \\ \\ \\ 1\\ previous\\ sexual\\ partner\\ 2\\ years\\ ago\ \(1\)\
\-\ meds\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ po\\ prednisone\\ taper\\ \\(currently\\ 20mg\\ qd\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ albuterol\ \(0\)\
\-\ \\ \\ \\ \\ \\ singular\ \(0\)\
\-\ \\ \\ \\ \\ \\ advair\ \(0\)\
\-\ \\ \\ \\ \\ \\ ocp\\ \ \(0\)\
\-\ allergies\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ pcn\ \(0\)\
\-\ 10\\-15\\%\\ of\\ all\\ intracranial\\ tumors\ \(2\)\
\-\ normal\\ volunteers\\ had\\ 10\\%\\ incidence\\ of\\ asymptomatic\\ adenomas\\ by\\ mri\ \(0\)\
\-\ found\\ in\\ 1\\.5\\-27\\%\\ of\\ autopsy\\ cases\ \(0\)\
\-\ patients\\ present\\ with\\ either\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ hormonal\\ abnormalities\ \(0\)\
\-\ \\ \\ \\ \\ \\ symptoms\\ of\\ compressive\\ lesion\\:\\ headache\\,\\ field\\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ defects\\ or\\ cranial\\ nerve\\ palsies\\ \\(cavernous\\ sinus\\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ invasion\\)\\ \ \(1\)\
\-\ genetic\\ association\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ men\\ type\\ 1\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ 30\\%\\ of\\ patients\\ have\\ pit\\ adenoma\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ triad\\ with\\ parathyroid\\ and\\ pancreatic\\ islet\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ tumors\ \(1\)\
\-\ \\ \\ \\ \\ \\ gsp\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ gene\\ that\\ encodes\\ alpha\\-subunit\\ of\\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ gtp\\-binding\\ protein\\ gs\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ mutation\\ leads\\ to\\ activation\\ of\\ camp\ \(0\)\
\-\ \\ \\ \\ \\ \\ present\\ in\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ 40\\%\\ of\\ gh\\-secretors\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ 10\\%\\ of\\ null\\ cell\\ \\(non\\-secretors\\)\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ 6\\%\\ of\\ acth\\-secretors\ \(0\)\
\-\ classification\\:\ \(2\)\
\-\ \\ \\ \\ \\ \\ based\\ on\\ size\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ macroadenoma\\ \\>\\ 1cm\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ microadenoma\\ \\<\\ 1cm\ \(0\)\
\-\ \\ \\ \\ \\ \\ based\\ on\\ what\\ the\\ tumor\\ secretes\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ prolactin\\,\\ gonadotropin\\,\\ gh\\,\\ acth\\,\\ tsh\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ nothin\\â\\€\\™\\ \\(null\\ cell\\)\ \(1\)\
\-\ surgery\\:\ \(7\)\
\-\ \\ \\ \\ \\ \\ for\\ most\\ non\\-prolactin\\ secreting\\ adenomas\ \(0\)\
\-\ \\ \\ \\ \\ \\ usually\\ trans\\-sphenoidal\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ mortality\\ \\<1\\%\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ common\\ complications\\:\\ nasal\\ septal\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ perforation\\,\\ ant\\.\\ pit\\ insufficiency\\,\\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ transient\\ diabetes\\ insipidus\\,\\ csf\\ leak\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ carotid\\ injury\\ and\\ vision\\ loss\\ are\\ rare\ \(0\)\
\-\ \\ \\ \\ \\ \\ success\\ measures\\ clinically\\ and\\ radiographically\ \(0\)\
\-\ \\ \\ \\ \\ \\ normalization\\ of\\ hormones\\ varies\\ with\\ type\\/size\\ of\\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ tumor\ \(2\)\
\-\ \\ \\ \\ \\ \\ normalization\\ of\\ visual\\ fields\\ \\=\\ 16\\-53\\%\ \(0\)\
\-\ \\ \\ \\ \\ \\ improvement\\ of\\ visual\\ fields\\ \\=\\ 26\\-70\\%\ \(0\)\
\-\ treatment\\ of\\ prolactinomas\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ medical\\ \\(dopamine\\ agonists\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\-\\ prl\\ secretion\\ inhibited\\ by\\ dopamine\\ secretion\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ from\\ the\\ hypothalamus\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\-\\ decreases\\ tumor\\ size\\ \\ \\ \\ \\ \\ \\(70\\-90\\%\\ of\\ cases\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\-\\ normalizes\\ prl\\ levels\\ \\ \\ \\ \\ \\(70\\-90\\%\\ of\\ cases\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\-\\ restores\\ ovulation\\/menses\\ \\(70\\-90\\%\\ of\\ cases\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\-\\ improves\\ visual\\ fields\\ \\ \\ \\ \\(70\\-90\\%\\ of\\ cases\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\"reversible\\,\\ therefore\\ lifelong\\ tx\\ is\\ rule\\"\ \(0\)\
\-\ drugs\\:\ \(2\)\
\-\ \\ \\ \\ \\ \\ bromocriptine\\ \\(classic\\â\\€\\”used\\ for\\ decades\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ side\\ effects\\:\\ n\\/v\\,\\ dizziness\\,\\ postural\\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ hypotension\\,\\ ha\\â\\€\\™s\ \(0\)\
\-\ newer\\ agents\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ lisuride\ \(0\)\
\-\ \\ \\ \\ \\ \\ pergolide\ \(0\)\
\-\ \\ \\ \\ \\ \\ cabergoline\ \(0\)\
\-\ new\\ txs\\ for\\ non\\-prl\\ adenomas\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ gh\\-secretors\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ somatostatin\\ analogs\\:\\ octreotide\\ \\&\\ lanreotide\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ reduce\\ gh\\ levels\\ in\\ 90\\%\\ of\\ pts\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ achieve\\ complete\\ suppression\\ in\\ 50\\%\\ of\\ pts\ \(1\)\
\-\ radiation\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ usually\\ reserved\\ for\\ residual\\ dz\\ or\\ recurrence\\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ after\\ surgery\ \(1\)\
\-\ \\ \\ \\ \\ \\ average\\ total\\ dose\\ \\=\\ 45\\-50\\ gy\ \(0\)\
\-\ \\ \\ \\ \\ \\ control\\ rates\\ of\\ 85\\-95\\%\\ \\@\\ 10\\ years\ \(0\)\
\-\ 3\\ types\\:\ \(1\)\
\-\ \\ \\ \\ \\ \\ standard\ \(0\)\
\-\ \\ \\ \\ \\ \\ stereotactic\\ fractionated\ \(0\)\
\-\ \\ \\ \\ \\ \\ stereotactic\\ radiosurgery\\ \\(single\\ dose\\ \\/\\ gamma\\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ knife\\)\ \(1\)\
\-\ disadvantages\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ slower\\ reversal\\ of\\ neurologic\\ symptoms\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ slower\\ drop\\ in\\ hormonal\\ levels\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ hypopituitarism\\:\\ 50\\%\\ of\\ pts\\ will\\ have\\ at\\ least\\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ one\\ pit\\ hormone\\ deficiency\\ \\@\\ 5\\ yrs\\ \\ \\ \\ \\ \\ \\ lifelong\\ \\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ follow\\-up\ \(1\)\
\-\ secondary\\ brain\\ tumor\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ risk\\ of\\ 1\\.3\\-1\\.7\\%\\ \\@\\ 10\\ yrs\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ risk\\ of\\ 1\\.9\\-2\\.7\\%\\ \\@\\ 20\\ yrs\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\(relative\\ risk\\ of\\ 9\\.3\\-16\\ x\\ general\\ population\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ radiation\\-induced\\ optic\\ neuropathy\\/retinopathy\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ low\\ risk\\:\\ 0\\.7\\-2\\%\ \(0\)\
\-\ srs\\(stereotactic\\ radiosurgery\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ quicker\\ drop\\ in\\ hormone\\ levels\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ adverse\\ cns\\ effects\\ in\\ 28\\%\\ of\\ cases\\ at\\ 3\\ yrs\\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ compared\\ with\\ 0\\%\\ with\\ fsrt3\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\"not\\ recommended\\ \\!\\!\\"\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ou\\:\\ 0\\.4209889482193316\ \(0\)\
\-\ od\\:\\ 0\\.24080320061060936\ \(0\)\
\-\ of\\:\\ 0\\.1518692392938945\ \(0\)\
\-\ pit\\:\\ 0\\.14885518247933321\ \(0\)\
\-\ gh\\:\\ 0\\.14275181432869413\ \(0\)\
\-\ prl\\:\\ 0\\.12410703571764534\ \(0\)\
\-\ 90\\:\\ 0\\.12402300446951964\ \(0\)\
\-\ yrs\\:\\ 0\\.11518325118936057\ \(0\)\
\-\ optic\\:\\ 0\\.11133879396989461\ \(0\)\
\-\ visual\\:\\ 0\\.11035280754087626\ \(0\)\
\-\ null\\:\\ 0\\.10916099889179097\ \(0\)\
\-\ cases\\:\\ 0\\.10439473799386637\ \(0\)\
\-\ fields\\:\\ 0\\.10177909953027103\ \(0\)\
\-\ pts\\:\\ 0\\.09347940623016777\ \(0\)\
\-\ stereotactic\\:\\ 0\\.09211782392066621\ \(0\)\
\-\ 10\\:\\ 0\\.09075873935593869\ \(0\)\
\-\ adenomas\\:\\ 0\\.09030120022897851\ \(0\)\
\-\ disc\\:\\ 0\\.08989569045439827\ \(0\)\
\-\ vision\\:\\ 0\\.08961661891914184\ \(0\)\
\-\ os\\:\\ 0\\.08236780466665308\ \(0\)\
\-\ levels\\:\\ 0\\.08203244486078222\ \(0\)\
\-\ flat\\:\\ 0\\.080315939338542\ \(0\)\
\-\ dopamine\\:\\ 0\\.0790605988154648\ \(0\)\
\-\ asthma\\:\\ 0\\.07738946324267296\ \(0\)\
\-\ apd\\:\\ 0\\.07645142425749274\ \(0\)\
\-\ bartonella\\:\\ 0\\.07442759123966661\ \(0\)\
\-\ risk\\:\\ 0\\.07393346706702503\ \(0\)\
\-\ advair\\:\\ 0\\.07277399926119399\ \(0\)\
\-\ taper\\:\\ 0\\.07016482470322193\ \(0\)\
\-\ normalization\\:\\ 0\\.07016482470322193\ \(0\)\
\-\ lifelong\\:\\ 0\\.06909657426489521\ \(0\)\
\-\ slower\\:\\ 0\\.06909657426489521\ \(0\)\
\-\ acth\\:\\ 0\\.06727656209427878\ \(0\)\
\-\ radiosurgery\\:\\ 0\\.06648739970692316\ \(0\)\
\-\ secretion\\:\\ 0\\.06576144068336255\ \(0\)\
\-\ albuterol\\:\\ 0\\.06446356668909702\ \(0\)\
\-\ secreting\\:\\ 0\\.06446356668909702\ \(0\)\
\-\ hormonal\\:\\ 0\\.06387822514895111\ \(0\)\
\-\ prolactin\\:\\ 0\\.06387822514895111\ \(0\)\
\-\ loss\\:\\ 0\\.06303961792413744\ \(0\)\
\-\ she\\:\\ 0\\.06159508407903232\ \(0\)\
\-\ 16\\:\\ 0\\.06047225647710139\ \(0\)\
\-\ macroadenoma\\:\\ 0\\.05983055911329881\ \(0\)\
\-\ no\\:\\ 0\\.05888449307330335\ \(0\)\
\-\ and\\:\\ 0\\.05879899785255657\ \(0\)\
\-\ in\\:\\ 0\\.057916697689790644\ \(0\)\
\-\ lyme\\:\\ 0\\.05677887503797927\ \(0\)\
\-\ symptoms\\:\\ 0\\.05661463072702727\ \(0\)\
\-\ neuropathy\\:\\ 0\\.056523375156353584\ \(0\)\
\-\ meds\\:\\ 0\\.056523375156353584\ \(0\)\
\-\ compressive\\:\\ 0\\.05627487615967681\ \(0\)\
\-\ drop\\:\\ 0\\.05627487615967681\ \(0\)\
\-\ nerve\\:\\ 0\\.055362891867016636\ \(0\)\
\-\ 1cm\\:\\ 0\\.05491186977776872\ \(0\)\
\-\ 50\\:\\ 0\\.054197270666445745\ \(0\)\
\-\ tumor\\:\\ 0\\.05412244606214719\ \(0\)\
\-\ effects\\:\\ 0\\.05372719096265974\ \(0\)\
\-\ po\\:\\ 0\\.053015481189478665\ \(0\)\
\-\ hormone\\:\\ 0\\.05267952996791099\ \(0\)\
\-\ size\\:\\ 0\\.052546220649335486\ \(0\)\
\-\ 20\\:\\ 0\\.050065832681626565\ \(0\)\
\-\ what\\:\\ 0\\.049746405044903554\ \(0\)\
\-\ field\\:\\ 0\\.0486252702234979\ \(0\)\
\-\ dose\\:\\ 0\\.04831428046534438\ \(0\)\
\-\ gross\\:\\ 0\\.045911243098867634\ \(0\)\
\-\ to\\:\\ 0\\.045269135014176905\ \(0\)\
\-\ or\\:\\ 0\\.04499557065922045\ \(0\)\
\-\ cell\\:\\ 0\\.04439354461779266\ \(0\)\
\-\ started\\:\\ 0\\.04357993500845841\ \(0\)\
\-\ intracranial\\:\\ 0\\.04162895094454571\ \(0\)\
\-\ myope\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ nicking\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ sheathing\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ neuroretinitis\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ flavimaculatus\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ reservist\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ singulaire\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ curtain\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ floaters\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ photopsia\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ amaurosis\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ pcn\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ volunteers\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ gsp\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ secretes\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ nothin\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ restores\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ lisuride\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ pergolide\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ cabergoline\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ txs\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ lanreotide\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ fractionated\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ srs\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ fsrt3\\:\\ 0\\.04136901190588178\ \(0\)\
\-\ neurologic\\:\\ 0\\.04134100148983988\ \(0\)\
\-\ adenoma\\:\\ 0\\.041247014679843715\ \(0\)\
\-\ single\\:\\ 0\\.03978238049433397\ \(0\)\
\-\ bcva\\:\\ 0\\.0395302994077324\ \(0\)\
\-\ brightness\\:\\ 0\\.0395302994077324\ \(0\)\
\-\ dfe\\:\\ 0\\.0395302994077324\ \(0\)\
\-\ monocular\\:\\ 0\\.0395302994077324\ \(0\)\
\-\ craniopharygioma\\:\\ 0\\.0395302994077324\ \(0\)\
\-\ encodes\\:\\ 0\\.0395302994077324\ \(0\)\
\-\ prolactinomas\\:\\ 0\\.0395302994077324\ \(0\)\
\-\ inhibited\\:\\ 0\\.0395302994077324\ \(0\)\
\-\ normalizes\\:\\ 0\\.0395302994077324\ \(0\)\
\-\ for\\:\\ 0\\.039202386297311716\ \(0\)\
\-\ rare\\:\\ 0\\.03905642147077336\ \(0\)\
\-\ fd\\:\\ 0\\.03822571212874637\ \(0\)\
\-\ macula\\:\\ 0\\.03822571212874637\ \(0\)\
\-\ pinpoint\\:\\ 0\\.03822571212874637\ \(0\)\
\-\ partner\\:\\ 0\\.03822571212874637\ \(0\)\
\-\ singular\\:\\ 0\\.03822571212874637\ \(0\)\
\-\ ant\\:\\ 0\\.03822571212874637\ \(0\)\
\-\ disadvantages\\:\\ 0\\.03822571212874637\ \(0\)\
\-\ quicker\\:\\ 0\\.03822571212874637\ \(0\)\
\-\ tumors\\:\\ 0\\.03804957713025871\ \(0\)\
\-\ abnormalities\\:\\ 0\\.037476566857819325\ \(0\)\
\-\ based\\:\\ 0\\.037476566857819325\ \(0\)\
\-\ confrontation\\:\\ 0\\.037213795619833304\ \(0\)\
\-\ activated\\:\\ 0\\.037213795619833304\ \(0\)\
\-\ moment\\:\\ 0\\.037213795619833304\ \(0\)\
\-\ ocp\\:\\ 0\\.037213795619833304\ \(0\)\
\-\ somatostatin\\:\\ 0\\.037213795619833304\ \(0\)\
\-\ analogs\\:\\ 0\\.037213795619833304\ \(0\)\
\-\ lesion\\:\\ 0\\.037205487244791745\ \(0\)\
\-\ then\\:\\ 0\\.03662336207754227\ \(0\)\
\-\ dd\\:\\ 0\\.036386999630596994\ \(0\)\
\-\ initiating\\:\\ 0\\.036386999630596994\ \(0\)\
\-\ 20mg\\:\\ 0\\.036386999630596994\ \(0\)\
\-\ gs\\:\\ 0\\.036386999630596994\ \(0\)\
\-\ hypopituitarism\\:\\ 0\\.036386999630596994\ \(0\)\
\-\ new\\:\\ 0\\.035792178089141494\ \(0\)\
\-\ drusen\\:\\ 0\\.03568795358217353\ \(0\)\
\-\ camp\\:\\ 0\\.03568795358217353\ \(0\)\
\-\ insipidus\\:\\ 0\\.03568795358217353\ \(0\)\
\-\ agonists\\:\\ 0\\.03568795358217353\ \(0\)\
\-\ bromocriptine\\:\\ 0\\.03568795358217353\ \(0\)\
\-\ achieve\\:\\ 0\\.03568795358217353\ \(0\)\
\-\ headache\\:\\ 0\\.03566497199268037\ \(0\)\
\-\ iop\\:\\ 0\\.03508241235161096\ \(0\)\
\-\ hypopigmented\\:\\ 0\\.03508241235161096\ \(0\)\
\-\ germany\\:\\ 0\\.03508241235161096\ \(0\)\
\-\ parasthesias\\:\\ 0\\.03508241235161096\ \(0\)\
\-\ activation\\:\\ 0\\.03508241235161096\ \(0\)\
\-\ gonadotropin\\:\\ 0\\.03508241235161096\ \(0\)\
\-\ gy\\:\\ 0\\.03508241235161096\ \(0\)\
\-\ type\\:\\ 0\\.03470686340118828\ \(0\)\
\-\ unremarkable\\:\\ 0\\.03468416089621554\ \(0\)\
\-\ desaturation\\:\\ 0\\.034548287132447605\ \(0\)\
\-\ retrobulbar\\:\\ 0\\.034548287132447605\ \(0\)\
\-\ pulmonology\\:\\ 0\\.034548287132447605\ \(0\)\
\-\ palsies\\:\\ 0\\.034548287132447605\ \(0\)\
\-\ hormones\\:\\ 0\\.034548287132447605\ \(0\)\
\-\ radiation\\:\\ 0\\.03428494332741876\ \(0\)\
\-\ serology\\:\\ 0\\.03407049584269789\ \(0\)\
\-\ intrasellar\\:\\ 0\\.03407049584269789\ \(0\)\
\-\ burst\\:\\ 0\\.03407049584269789\ \(0\)\
\-\ microadenoma\\:\\ 0\\.03407049584269789\ \(0\)\
\-\ newer\\:\\ 0\\.03407049584269789\ \(0\)\
\-\ octreotide\\:\\ 0\\.03407049584269789\ \(0\)\
\-\ fh\\:\\ 0\\.03363828104713939\ \(0\)\
\-\ sexual\\:\\ 0\\.03363828104713939\ \(0\)\
\-\ wramc\\:\\ 0\\.03324369985346158\ \(0\)\
\-\ improves\\:\\ 0\\.03324369985346158\ \(0\)\
\-\ onset\\:\\ 0\\.03322151588628148\ \(0\)\
\-\ tortuosity\\:\\ 0\\.032880720341681276\ \(0\)\
\-\ iraq\\:\\ 0\\.032880720341681276\ \(0\)\
\-\ recall\\:\\ 0\\.032880720341681276\ \(0\)\
\-\ usually\\:\\ 0\\.03257008189995831\ \(0\)\
\-\ motility\\:\\ 0\\.03223178334454851\ \(0\)\
\-\ islet\\:\\ 0\\.03223178334454851\ \(0\)\
\-\ dz\\:\\ 0\\.03223178334454851\ \(0\)\
\-\ adverse\\:\\ 0\\.03223178334454851\ \(0\)\
\-\ years\\:\\ 0\\.031713819482739436\ \(0\)\
\-\ normal\\:\\ 0\\.03168553630420748\ \(0\)\
\-\ debulking\\:\\ 0\\.03166419064506573\ \(0\)\
\-\ autopsy\\:\\ 0\\.03166419064506573\ \(0\)\
\-\ hypothalamus\\:\\ 0\\.0314049873553122\ \(0\)\
\-\ dysarthria\\:\\ 0\\.031159802076722594\ \(0\)\
\-\ clock\\:\\ 0\\.03092719606556248\ \(0\)\
\-\ decreases\\:\\ 0\\.030705941306888737\ \(0\)\
\-\ postural\\:\\ 0\\.030705941306888737\ \(0\)\
\-\ triad\\:\\ 0\\.03049498127000398\ \(0\)\
\-\ suppression\\:\\ 0\\.03049498127000398\ \(0\)\
\-\ pip\\:\\ 0\\.030293400394684967\ \(0\)\
\-\ syphilis\\:\\ 0\\.030293400394684967\ \(0\)\
\-\ retinal\\:\\ 0\\.030293400394684967\ \(0\)\
\-\ my\\:\\ 0\\.030293400394684967\ \(0\)\
\-\ gene\\:\\ 0\\.030293400394684967\ \(0\)\
\-\ presumably\\:\\ 0\\.03010040007632617\ \(0\)\
\-\ ha\\:\\ 0\\.03010040007632617\ \(0\)\
\-\ reserved\\:\\ 0\\.03010040007632617\ \(0\)\
\-\ deployed\\:\\ 0\\.029915279556649407\ \(0\)\
\-\ evacuated\\:\\ 0\\.029915279556649407\ \(0\)\
\-\ qd\\:\\ 0\\.029915279556649407\ \(0\)\
\-\ reversible\\:\\ 0\\.029915279556649407\ \(0\)\
\-\ etoh\\:\\ 0\\.02973742056454587\ \(0\)\
\-\ varies\\:\\ 0\\.02973742056454587\ \(0\)\
\-\ low\\:\\ 0\\.029686718712760844\ \(0\)\
\-\ march\\:\\ 0\\.02940135402790271\ \(0\)\
\-\ july\\:\\ 0\\.02940135402790271\ \(0\)\
\-\ reversal\\:\\ 0\\.02940135402790271\ \(0\)\
\-\ orbits\\:\\ 0\\.029242221103704637\ \(0\)\
\-\ person\\:\\ 0\\.029242221103704637\ \(0\)\
\-\ decades\\:\\ 0\\.029242221103704637\ \(0\)\
\-\ patients\\:\\ 0\\.029104644924767383\ \(0\)\
\-\ dx\\:\\ 0\\.029088483567413097\ \(0\)\
\-\ mutation\\:\\ 0\\.029088483567413097\ \(0\)\
\-\ 3mm\\:\\ 0\\.02893978752469306\ \(0\)\
\-\ neuritis\\:\\ 0\\.028795812797340142\ \(0\)\
\-\ knife\\:\\ 0\\.028656268771854593\ \(0\)\
\-\ parathyroid\\:\\ 0\\.028389437518989636\ \(0\)\
\-\ tx\\:\\ 0\\.028389437518989636\ \(0\)\
\-\ photophobia\\:\\ 0\\.028261687578176792\ \(0\)\
\-\ success\\:\\ 0\\.028016502299587184\ \(0\)\
\-\ hypotension\\:\\ 0\\.028016502299587184\ \(0\)\
\-\ gamma\\:\\ 0\\.027898708066396487\ \(0\)\
\-\ surgery\\:\\ 0\\.027815763324407276\ \(0\)\
\-\ confusion\\:\\ 0\\.027671919660909802\ \(0\)\
\-\ leak\\:\\ 0\\.027671919660909802\ \(0\)\
\-\ sle\\:\\ 0\\.02745593488888436\ \(0\)\
\-\ doing\\:\\ 0\\.02745593488888436\ \(0\)\
\-\ prednisone\\:\\ 0\\.027249771069263715\ \(0\)\
\-\ caliber\\:\\ 0\\.027150100617549557\ \(0\)\
\-\ ica\\:\\ 0\\.02705257378346004\ \(0\)\
\-\ diplopia\\:\\ 0\\.02705257378346004\ \(0\)\
\-\ agents\\:\\ 0\\.02705257378346004\ \(0\)\
\-\ average\\:\\ 0\\.02695710029919076\ \(0\)\
\-\ rates\\:\\ 0\\.02695710029919076\ \(0\)\
\-\ most\\:\\ 0\\.0269252729010107\ \(0\)\
\-\ fundus\\:\\ 0\\.02686359548132987\ \(0\)\
\-\ social\\:\\ 0\\.02686359548132987\ \(0\)\
\-\ classification\\:\\ 0\\.02659412078741046\ \(0\)\
\-\ mri\\:\\ 0\\.026556959727750306\ \(0\)\
\-\ present\\:\\ 0\\.026547709705529842\ \(0\)\
\-\ shortly\\:\\ 0\\.026507740594739333\ \(0\)\
\-\ toxic\\:\\ 0\\.026422975080027406\ \(0\)\
\-\ falling\\:\\ 0\\.026339764983955495\ \(0\)\
\-\ men\\:\\ 0\\.026339764983955495\ \(0\)\
\-\ reduce\\:\\ 0\\.026339764983955495\ \(0\)\
\-\ uncomplicated\\:\\ 0\\.0262580542507673\ \(0\)\
\-\ periphery\\:\\ 0\\.026098921326569227\ \(0\)\
\-\ leads\\:\\ 0\\.026098921326569227\ \(0\)\
\-\ drugs\\:\\ 0\\.02587022633160712\ \(0\)\
\-\ have\\:\\ 0\\.02584524995456924\ \(0\)\
\-\ radiographically\\:\\ 0\\.02579648774755765\ \(0\)\
\-\ pupils\\:\\ 0\\.025652513020204732\ \(0\)\
\-\ but\\:\\ 0\\.02558381016441962\ \(0\)\
\-\ remained\\:\\ 0\\.025582204278497386\ \(0\)\
\-\ genetic\\:\\ 0\\.025512968994719182\ \(0\)\
\-\ sharp\\:\\ 0\\.02544477488256776\ \(0\)\
\-\ mortality\\:\\ 0\\.02544477488256776\ \(0\)\
\-\ transient\\:\\ 0\\.02544477488256776\ \(0\)\
\-\ suprasellar\\:\\ 0\\.02537759109079491\ \(0\)\
\-\ with\\:\\ 0\\.025326663521364028\ \(0\)\
\-\ deficiency\\:\\ 0\\.025311388119400174\ \(0\)\
\-\ dizziness\\:\\ 0\\.025246137741854226\ \(0\)\
\-\ nor\\:\\ 0\\.025181812932839\ \(0\)\
\-\ septal\\:\\ 0\\.025181812932839\ \(0\)\
\-\ ms\\:\\ 0\\.02511838780104138\ \(0\)\
\-\ after\\:\\ 0\\.025098253760658194\ \(0\)\
\-\ tsh\\:\\ 0\\.024994138302702994\ \(0\)\
\-\ steroid\\:\\ 0\\.024933267281364614\ \(0\)\
\-\ insufficiency\\:\\ 0\\.024933267281364614\ \(0\)\
\-\ population\\:\\ 0\\.024473651659234954\ \(0\)\
\-\ perforation\\:\\ 0\\.024419341752617917\ \(0\)\
\-\ red\\:\\ 0\\.024365674581881838\ \(0\)\
\-\ sarcoid\\:\\ 0\\.02426020882841985\ \(0\)\
\-\ next\\:\\ 0\\.02415714023267219\ \(0\)\
\-\ cns\\:\\ 0\\.02415714023267219\ \(0\)\
\-\ standing\\:\\ 0\\.024056362240837615\ \(0\)\
\-\ began\\:\\ 0\\.024056362240837615\ \(0\)\
\-\ types\\:\\ 0\\.024056362240837615\ \(0\)\
\-\ protein\\:\\ 0\\.024006800840414146\ \(0\)\
\-\ standard\\:\\ 0\\.024006800840414146\ \(0\)\
\-\ painless\\:\\ 0\\.023957775249408265\ \(0\)\
\-\ least\\:\\ 0\\.02390927400632463\ \(0\)\
\-\ pituitary\\:\\ 0\\.0238612860135387\ \(0\)\
\-\ diabetes\\:\\ 0\\.023628680002378586\ \(0\)\
\-\ nasal\\:\\ 0\\.02358355701316305\ \(0\)\
\-\ hx\\:\\ 0\\.02353887859264553\ \(0\)\
\-\ residual\\:\\ 0\\.02353887859264553\ \(0\)\
\-\ pancreatic\\:\\ 0\\.02345082101027505\ \(0\)\
\-\ on\\:\\ 0\\.02343799411113268\ \(0\)\
\-\ denied\\:\\ 0\\.023364440817603922\ \(0\)\
\-\ color\\:\\ 0\\.023321860007096743\ \(0\)\
\-\ association\\:\\ 0\\.023279675302891996\ \(0\)\
\-\ invasion\\:\\ 0\\.023074444670433923\ \(0\)\
\-\ relative\\:\\ 0\\.022916695791111694\ \(0\)\
\-\ ischemic\\:\\ 0\\.02287810131985554\ \(0\)\
\-\ therefore\\:\\ 0\\.022801884013142277\ \(0\)\
\-\ dyspnea\\:\\ 0\\.02276425041126158\ \(0\)\
\-\ 75\\:\\ 0\\.02268990738562501\ \(0\)\
\-\ margin\\:\\ 0\\.02268990738562501\ \(0\)\
\-\ improvement\\:\\ 0\\.022580629254468538\ \(0\)\
\-\ cavernous\\:\\ 0\\.02243890450136198\ \(0\)\
\-\ light\\:\\ 0\\.02240415472978546\ \(0\)\
\-\ unable\\:\\ 0\\.02240415472978546\ \(0\)\
\-\ sudden\\:\\ 0\\.022369669217583772\ \(0\)\
\-\ subtle\\:\\ 0\\.02230147510543235\ \(0\)\
\-\ defects\\:\\ 0\\.02230147510543235\ \(0\)\
\-\ incidence\\:\\ 0\\.022267758793978923\ \(0\)\
\-\ control\\:\\ 0\\.022102837964718815\ \(0\)\
\-\ subsequently\\:\\ 0\\.02207056150817525\ \(0\)\
\-\ glioma\\:\\ 0\\.02197508802390597\ \(0\)\
\-\ by\\:\\ 0\\.021970344304259197\ \(0\)\
\-\ carotid\\:\\ 0\\.021789967504229204\ \(0\)\
\-\ clinically\\:\\ 0\\.02149729673415625\ \(0\)\
\-\ 28\\:\\ 0\\.0214690422938413\ \(0\)\
\-\ either\\:\\ 0\\.02138532010663898\ \(0\)\
\-\ segment\\:\\ 0\\.021357752708670703\ \(0\)\
\-\ recurrence\\:\\ 0\\.021357752708670703\ \(0\)\
\-\ total\\:\\ 0\\.02119577752615301\ \(0\)\
\-\ cranial\\:\\ 0\\.021143046432002047\ \(0\)\
\-\ measures\\:\\ 0\\.021090921455805742\ \(0\)\
\-\ compared\\:\\ 0\\.020913062463702205\ \(0\)\
\-\ inflammation\\:\\ 0\\.020790160009187927\ \(0\)\
\-\ general\\:\\ 0\\.020765974229189226\ \(0\)\
\-\ just\\:\\ 0\\.020694181336592992\ \(0\)\
\-\ eye\\:\\ 0\\.020694181336592992\ \(0\)\
\-\ 21\\:\\ 0\\.02067050074491994\ \(0\)\
\-\ recommended\\:\\ 0\\.020576995927059045\ \(0\)\
\-\ rule\\:\\ 0\\.020530956719434394\ \(0\)\
\-\ stable\\:\\ 0\\.020462762607282962\ \(0\)\
\-\ csf\\:\\ 0\\.02044025723602764\ \(0\)\
\-\ full\\:\\ 0\\.020221141040468515\ \(0\)\
\-\ slightly\\:\\ 0\\.020178560229961336\ \(0\)\
\-\ vessels\\:\\ 0\\.020073825251297556\ \(0\)\
\-\ made\\:\\ 0\\.019951255006079825\ \(0\)\
\-\ currently\\:\\ 0\\.01987134416297301\ \(0\)\
\-\ complications\\:\\ 0\\.01981232177229841\ \(0\)\
\-\ attenuation\\:\\ 0\\.019792817127174015\ \(0\)\
\-\ mass\\:\\ 0\\.01976198510884314\ \(0\)\
\-\ hours\\:\\ 0\\.019715626786876824\ \(0\)\
\-\ aneurysm\\:\\ 0\\.019696532767086657\ \(0\)\
\-\ previous\\:\\ 0\\.0195466076084896\ \(0\)\
\-\ at\\:\\ 0\\.01954155398430109\ \(0\)\
\-\ process\\:\\ 0\\.01940148088748118\ \(0\)\
\-\ meningioma\\:\\ 0\\.019383662306597046\ \(0\)\
\-\ 40\\:\\ 0\\.019024788565129354\ \(0\)\
\-\ defect\\:\\ 0\\.018975762974123473\ \(0\)\
\-\ ago\\:\\ 0\\.01892726173103984\ \(0\)\
\-\ weakness\\:\\ 0\\.01887927373825391\ \(0\)\
\-\ clear\\:\\ 0\\.01875373428883287\ \(0\)\
\-\ sinus\\:\\ 0\\.018692244221285004\ \(0\)\
\-\ reported\\:\\ 0\\.018631576788040696\ \(0\)\
\-\ mid\\:\\ 0\\.01861653590194537\ \(0\)\
\-\ complete\\:\\ 0\\.0181327421983471\ \(0\)\
\-\ was\\:\\ 0\\.018030703657052692\ \(0\)\
\-\ side\\:\\ 0\\.01787054067840137\ \(0\)\
\-\ 30\\:\\ 0\\.017646860232052516\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.017610629762368726\ \(0\)\
\-\ inferior\\:\\ 0\\.017598616979183742\ \(0\)\
\-\ recent\\:\\ 0\\.01751540688311183\ \(0\)\
\-\ inflammatory\\:\\ 0\\.01749191033831477\ \(0\)\
\-\ central\\:\\ 0\\.017274563225725566\ \(0\)\
\-\ white\\:\\ 0\\.017067158518697945\ \(0\)\
\-\ air\\:\\ 0\\.016920183798071264\ \(0\)\
\-\ injury\\:\\ 0\\.01686882625028279\ \(0\)\
\-\ found\\:\\ 0\\.016737956571205904\ \(0\)\
\-\ any\\:\\ 0\\.016718153819211354\ \(0\)\
\-\ will\\:\\ 0\\.016649517350038605\ \(0\)\
\-\ medical\\:\\ 0\\.01644032700020089\ \(0\)\
\-\ diffuse\\:\\ 0\\.016222613688798505\ \(0\)\
\-\ her\\:\\ 0\\.01616103415671726\ \(0\)\
\-\ brain\\:\\ 0\\.01612621768626811\ \(0\)\
\-\ see\\:\\ 0\\.016091666486741596\ \(0\)\
\-\ evaluation\\:\\ 0\\.01577592860725003\ \(0\)\
\-\ changes\\:\\ 0\\.015633709958861527\ \(0\)\
\-\ when\\:\\ 0\\.015625938195176117\ \(0\)\
\-\ weeks\\:\\ 0\\.015503367949958385\ \(0\)\
\-\ the\\:\\ 0\\.01548497780711866\ \(0\)\
\-\ likely\\:\\ 0\\.015458244960742848\ \(0\)\
\-\ all\\:\\ 0\\.01539877101975808\ \(0\)\
\-\ secondary\\:\\ 0\\.015332782131828529\ \(0\)\
\-\ one\\:\\ 0\\.014810804851889223\ \(0\)\
\-\ common\\:\\ 0\\.01467027796526272\ \(0\)\
\-\ these\\:\\ 0\\.014607813850932896\ \(0\)\
\-\ anterior\\:\\ 0\\.014443336156768712\ \(0\)\
\-\ over\\:\\ 0\\.014383901190649123\ \(0\)\
\-\ is\\:\\ 0\\.014168408675435014\ \(0\)\
\-\ increased\\:\\ 0\\.013988335984164917\ \(0\)\
\-\ into\\:\\ 0\\.01375113254344274\ \(0\)\
\-\ can\\:\\ 0\\.013574854042075946\ \(0\)\
\-\ woman\\:\\ 0\\.013472285013720754\ \(0\)\
\-\ diagnosis\\:\\ 0\\.013409933212815838\ \(0\)\
\-\ large\\:\\ 0\\.012961292579641666\ \(0\)\
\-\ had\\:\\ 0\\.01288852840311658\ \(0\)\
\-\ surgical\\:\\ 0\\.012572828099789114\ \(0\)\
\-\ treatment\\:\\ 0\\.012322434570942275\ \(0\)\
\-\ that\\:\\ 0\\.011225863594235528\ \(0\)\
\-\ disease\\:\\ 0\\.010858585135544305\ \(0\)\
\-\ from\\:\\ 0\\.010273784275007887\ \(0\)\
\-\ not\\:\\ 0\\.010212181761352654\ \(0\)\
\-\ are\\:\\ 0\\.009815835930646093\ \(0\)\
\-\ pain\\:\\ 0\\.009256622714986411\ \(0\)\
\-\ right\\:\\ 0\\.008576405275435543\ \(0\)\
